5-bromo-toluene-3-sulfonic acid amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-toluene-3-sulfonic acid amide
• 英文别名: 5-Brom-toluol-3-sulfonsaeure-amid；3-Bromo-5-methylbenzenesulfonamide
• 化学式: C₇H₈BrNO₂S
• 分子量: 250.116
• InChiKey: NZLBCZUPIAFSIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-toluene-3-sulfonic acid amide 在 palladium diacetate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 盐酸 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 3-((4-((5-fluoro-6-methyl-1H-indazol-3-yl)(methyl)amino)pyrimidin-2-yl)amino)-5-methylbenzenesulfonamide
  参考文献：
  名称：

  [EN] INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
  [FR] INDAZOLYL-PYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  揭示了具有以下公式的化合物：或其盐，其中A、n、R1、R1A和R2如本文所定义，并且揭示了制备和使用这些化合物的方法。

  公开号：

  WO2011120025A1
• 作为产物：
  描述：

  3-溴-5-甲基苯磺酰氯 在 氨 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以74%的产率得到5-bromo-toluene-3-sulfonic acid amide
  参考文献：
  名称：

  [EN] INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
  [FR] INDAZOLYL-PYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  揭示了具有以下公式的化合物：或其盐，其中A、n、R1、R1A和R2如本文所定义，并且揭示了制备和使用这些化合物的方法。

  公开号：

  WO2011120025A1

文献信息

• Phenethanolamine derivatives for treatment of respiratory diseases
  申请人：——

  公开号：US20040180876A1

  公开（公告）日：2004-09-16

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及一种新型化合物(I)、其制造方法、包含它们的药物组合物以及它们在治疗中的应用，特别是在呼吸系统疾病的预防和治疗中的应用。
• PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
  申请人：BIGGADIKE Keith

  公开号：US20060287286A1

  公开（公告）日：2006-12-21

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物、其制备方法、含有它们的制药组合物以及它们在治疗中的应用，特别是它们在预防和治疗呼吸系统疾病中的应用。
• Methods using phenethanolamine derivatives for treatment of respiratory diseases
  申请人：Biggadike Keith

  公开号：US20070004807A1

  公开（公告）日：2007-01-04

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物、其制造方法、含有它们的药物组合物，以及它们在治疗中的应用，特别是在呼吸系统疾病的预防和治疗中的应用。
• Synthesis and Biochemical Evaluation of Noncyclic Nucleotide Exchange Proteins Directly Activated by cAMP 1 (EPAC1) Regulators
  作者：Pingyuan Wang、Urszula Luchowska-Stańska、Boy van Basten、Haiying Chen、Zhiqing Liu、Jolanta Wiejak、Padraic Whelan、David Morgan、Emma Lochhead、Graeme Barker、Holger Rehmann、Stephen J. Yarwood、Jia Zhou

  DOI：10.1021/acs.jmedchem.9b02094

  日期：2020.5.28

  Exchange proteins directly activated by cAMP (EPAC) play a central role in various biological functions, and activation of the EPAC1 protein has shown potential benefits for the treatment of various human diseases. Herein, we report the synthesis and biochemical evaluation of a series of noncyclic nucleotide EPAC1 activators. Several potent EPAC1 binders were identified including 25g, 25q, 25n, 25u, 25e, and 25f, which promote EPAC1 guanine nucleotide exchange factor activity in vitro. These agonists can also activate EPAC1 protein in cells, where they exhibit excellent selectivity toward EPAC over protein kinase A and G protein-coupled receptors. Moreover, 25e, 25f, 25n, and 25u exhibited improved selectivity toward activation of EPAC1 over EPAC2 in cells. Of these, 25u was found to robustly inhibit IL-6-activated signal transducer and activator of transcription 3 (STAT3) and subsequent induction of the pro-inflammatory vascular cell adhesion molecule 1 (VCAM1) cell-adhesion protein. These novel EPAC1 activators may therefore act as useful pharmacological tools for elucidation of EPAC function and promising drug leads for the treatment of relevant human diseases.
• US7135600B2
  申请人：——

  公开号：US7135600B2

  公开（公告）日：2006-11-14